The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.

A growing number of employers are considering covering the blockbuster weight-loss drugs, several surveys show. Workers will learn whether they’ll gain such coverage for the coming year during open enrollment,

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding pharmacies to continue selling cheaper copycat versions—at least for now.